In Focus e-report on the future of antibody-based drug
The future of anti-body based drugs: Where are the opportunities and what does the future hold? Thisis a free 16 page e report, available here.
This report
Provides an overview of the monoclonal antibody (mAbs) industry: market value, key antibody-based drug players, opportunities and the future for the sector
Explore what’s next for antibody-based drugs and where the opportunity is coming from
Includes an interview with Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery
Shares significant future trends for the therapeutic antibody market
Key insights:
The global mAb market size was valued at $185.50 billion in 2021
Biopharmas originating in China will likely have greater influence on the industry by 2028
The lessons learned from mAb development for SARS-CoV-2 will likely provide an important platform for the scientific community
With over 10 biosimilars approved, Argentina and Brazil have the most biosimilar monoclonal antibodies approved in Latin America
